IDP-023

The NK cell therapy market is experiencing robust growth driven by increasing interest in immuno-oncology and advancements in cell engineering technologies, with significant expansion expected through 2034.

Indapta Therapeutics has secured $22.5 million in funding to accelerate clinical trials of its allogeneic Natural Killer (NK) cell therapy, IDP-023.

The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.

Indapta Therapeutics' IDP-023 demonstrated preliminary clinical activity in relapsed/refractory multiple myeloma patients, even at the lowest dose without a targeting antibody.

The FDA approved Embecta's tubeless patch pump for insulin delivery in adults with type 1 and type 2 diabetes, offering a 300-unit reservoir based on patient feedback.